Results from a randomized clinical trial showed that about 43% of patients with moderate to severe Hidradenitis Suppurativa achieved a significant reduction in abscess and inflammatory nodule count after 24 weeks of treatment with subcutaneously administered sonelokimab 120 mg. Sonelokimab, a smaller monoclonal antibody, has the potential to penetrate tissues better and provide longer-lasting effects. The therapy is being developed by MoonLake Immunotherapeutics.
SAN DIEGO — After 24 weeks of treatment with subcutaneously administered sonelokimab 120 mg, about 43% of patients with moderate to severe achieved a Hidradenitis Suppurativa Clinical Response , defined as at least a 75% reduction in total abscess and inflammatory nodule count with no increase in abscess or draining tunnel count relative to baseline, results from a randomized clinical trial showed., a dermatologist at St.
At 24 weeks, 43.3% of patients in the sonelokimab 120 mg arm achieved a HiSCR 75, compared with 34.8% of those in the sonelokimab 240 mg arm and 14.7% of those in the placebo arm, he reported. Meanwhile, 65.7% of patients in the sonelokimab 120 mg arm achieved an HiSCR 75, compared with 53% of those in the sonelokimab 240 mg arm and 27.9% of those in the placebo arm.
In addition, complete inflammatory remission as defined by the International HS Severity Score System continued to increase to week 24, with 24.1% of patients in the 120 mg arm achieving complete remission, compared with 15.5% of those in the 240 mg arm. Meaningful improvements in quality of life, skin pain, and HS symptoms reported by patients treated with sonelokimab were maintained or increased to week 24.
Sonelokimab Hidradenitis Suppurativa Clinical Trial Treatment Dermatology Moonlake Immunotherapeutics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Maternal Hidradenitis Suppurativa Linked to Risk for Childhood Morbidity: StudyThe study population included nearly 1.3 million children born in Quebec, Canada, over a 16-year period.
Read more »
Ruxolitinib Cream Shows Promise for Hidradenitis SuppurativaTreatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.
Read more »
Ruxolitinib Cream Shows Promise in Reducing Abscess and Inflammatory Nodule Count in Hidradenitis SuppurativaPatients with hidradenitis suppurativa (HS) who applied ruxolitinib cream experienced a greater reduction in the abscess and inflammatory nodule count compared to those who used a vehicle cream, according to a phase 2 trial.
Read more »
LIVE RESULTS: Florida’s presidential primary, results in northeast Florida local racesThough President Joe Biden and former president Donald Trump clinched enough delegates to win their respective party’s presidential nomination last week, voters in Florida will be going to the polls Tuesday to cast a vote in a Republican presidential primary.
Read more »
Illinois Primary Election Results 2024: See live results hereSeveral races still remain too close to call one day after Tuesday’s Illinois primary election. You can find live election results as they come in here.
Read more »
I’m a Woman Living With HS. Here’s How I Navigate Dating and RelationshipsHidradenitis suppurativa adds a layer of complexity to finding a relationship in a looks-driven world. Here's how Imani Futrell handles her dating life.
Read more »